Wegovy vs Saxenda: Key Differences for UK Patients

If you are exploring prescription weight loss injections in the UK, you may come across Wegovy and Saxenda. Both are GLP-1-based treatments from Novo Nordisk, used to support weight management — but they differ in their active ingredient, how often they are injected, the side effect experience, and how much weight loss is achievable.

This guide covers the key differences, including the direct head-to-head trial that compared them, what those differences mean in practice, and how to think about choosing an option that suits your routine, preferences, and health needs.

What Wegovy and Saxenda Are

Both medications are prescription-only injections used to support weight loss and weight management, prescribed alongside a reduced-calorie diet and increased physical activity. Both are made by Novo Nordisk.

While they share the same drug class and manufacturer, the longer-acting nature of semaglutide and the convenience of weekly dosing have made Wegovy the more widely-used option since its UK launch.

How They Work in the Body

Both Wegovy and Saxenda mimic glucagon-like peptide-1 (GLP-1), a naturally occurring hormone released by the gut after eating. GLP-1 is involved in:

• Appetite regulation — signalling fullness to the brain
• Gastric emptying — slowing how quickly food leaves the stomach
• Blood sugar control — stimulating insulin release when needed
• Reward signalling — modulating the desire for high-calorie food

By activating GLP-1 receptors, both medications reduce hunger, create earlier feelings of fullness, and gradually lower calorie intake.

The clinical difference comes down to duration of action:

• Semaglutide (Wegovy) has a half-life of approximately 7 days, allowing once-weekly dosing
• Liraglutide (Saxenda) has a half-life of approximately 13 hours, requiring daily dosing

This longer half-life is also part of why semaglutide produces stronger weight loss outcomes — receptor activation is more sustained.

Dosing Schedule: Once Weekly vs Daily

One of the most noticeable practical differences is injection frequency:

• Wegovy: once weekly — a single injection on the same day each week. Often perceived as more convenient and easier to remember.
• Saxenda: once daily — typically taken at the same time each day. May feel more natural for those already accustomed to daily medication routines.

Over the course of a year, Wegovy involves around 52 injections vs around 365 for Saxenda. For many patients, this is a meaningful adherence factor — daily medications are easier to forget, and missed doses can disrupt steady-state exposure.

Neither schedule is inherently better on clinical grounds. What matters is what fits your lifestyle and what you are likely to stick with for the months or years that treatment continues.

Typical Dose Progression

Wegovy (16-week titration)

• Weeks 1-4: 0.25mg once weekly
• Weeks 5-8: 0.5mg once weekly
• Weeks 9-12: 1mg once weekly
• Weeks 13-16: 1.7mg once weekly
• Week 17+: 2.4mg once weekly (maintenance dose)

Saxenda (5-week titration)

• Week 1: 0.6mg once daily
• Week 2: 1.2mg once daily
• Week 3: 1.8mg once daily
• Week 4: 2.4mg once daily
• Week 5+: 3.0mg once daily (maintenance dose)

Both follow a graduated approach to help the body adapt and reduce the intensity of gastrointestinal side effects. Wegovy’s slower titration reflects its weekly dosing schedule — each step needs more time to establish before moving up.

For detailed Wegovy dose escalation: Wegovy dosages explained 0.25mg to 2.4mg.

Weight Loss Outcomes: What Research Shows

Clinical trial data is where the comparison becomes clearest. Both medications have been studied extensively, and one trial — STEP 8 — directly compared them head-to-head.

Wegovy: STEP-1 trial (NEJM 2021)

The pivotal Phase 3 trial for Wegovy enrolled 1,961 adults with obesity or overweight with weight-related comorbidities. Over 68 weeks:

• Average weight loss: ~15% at the 2.4mg maintenance dose
• 86% achieved ≥5% weight loss
• 50% achieved ≥15% weight loss
• 32% achieved ≥20% weight loss

Saxenda: SCALE trial (NEJM 2015)

The pivotal trial for Saxenda enrolled 3,731 adults with obesity. Over 56 weeks:

• Average weight loss: ~8% at the 3mg maintenance dose
• 63% achieved ≥5% weight loss
• 33% achieved ≥10% weight loss

Head-to-Head: STEP 8 trial (JAMA 2022)

The most directly relevant comparison is the STEP 8 trial published in JAMA in 2022, which randomised 338 adults with overweight or obesity to receive once-weekly semaglutide 2.4mg or once-daily liraglutide 3.0mg over 68 weeks. The results showed:

For realistic timelines with Wegovy: how fast you can lose weight on Wegovy.

Side Effects and Tolerability

Both treatments cause similar side effects since they work via the same receptor pathway. Common effects, particularly during titration:

• Nausea — most common, usually temporary and worst during dose increases
• Vomiting — less common, often associated with overeating or rich foods
• Constipation — common, often improves with increased fluid and fibre intake
• Diarrhoea — also occurs in some patients
• Early fullness — the intended therapeutic effect
• Headaches — typically mild and transient
• Fatigue — particularly during initial weeks
• Injection site reactions — usually minor

The STEP 8 head-to-head trial found that fewer patients on semaglutide discontinued treatment due to side effects compared with liraglutide (3.2% vs 12.6%) — suggesting that despite the higher peak concentrations with weekly dosing, semaglutide tends to be better tolerated overall.

The experience of side effects also differs slightly due to the dosing schedule:

• Wegovy: nausea tends to be more concentrated around the day after each weekly injection, then settles
• Saxenda: side effects tend to be more steady-state — less intense peaks but more constant exposure

For practical strategies: Wegovy side effects and how to manage them.

UK Cost Comparison

Cost is a practical factor that influences the choice for many patients. At Slinic, Wegovy is priced across the dose ladder:

Saxenda pricing is broadly comparable on a monthly basis — across the UK market the maintenance 3mg dose typically falls in a similar range to Wegovy’s mid-doses. Because liraglutide has been available for longer, generic pricing pressure exists in some markets, though both remain branded-only in the UK.

When evaluating costs, look at the total cost over the expected treatment duration rather than just monthly figures. Given that Wegovy produces approximately 2.5× more weight loss per month in trials, the cost per kilogram lost tends to favour semaglutide significantly.

For full pricing detail: Wegovy cost UK 2026: private prescription prices explained.

Lifestyle and Routine Considerations

How treatment fits into daily life matters as much as clinical outcomes. The choice between weekly and daily dosing comes down to personal routine and preference.

Why some patients prefer Wegovy (weekly)

• One injection per week is easier to remember and harder to skip
• Travel is simpler — fewer doses to plan for and carry
• The “injection day” becomes a routine ritual rather than a daily reminder of treatment
• Less day-to-day attention required

Why some patients prefer Saxenda (daily)

• Daily routine feels more natural for those already taking daily medications
• If a dose is missed, less weight loss momentum is lost
• Side effects may feel less intense at peak (though more constant overall)
• More familiar approach for those used to insulin or other daily injections

The best choice is the one that feels manageable and sustainable for you over the long term — not the one that sounds easier on paper.

Choosing Between Treatments

There is no single “winner” for every patient, but the evidence does favour Wegovy in most cases. The right option depends on:

• Health history and contraindications — both medications share most warnings, but individual history may favour one
• Tolerance and side effect sensitivity — some patients tolerate one better than the other
• Daily routine and injection preferences — weekly vs daily fit
• Long-term goals — magnitude of weight loss target
• Response to previous treatments — if you have tried one without success, switching may make sense
• Budget considerations — though cost per kilogram lost tends to favour Wegovy

A clinician can help tailor the choice based on you, not population averages.

Clinician-Led Care at Slinic

At Slinic, treatment decisions are guided by clinical suitability and patient preference, not trends or sales. Patients receive personalised assessment, clear explanations of options based on trial evidence, support with dosing and tolerance, and ongoing pharmacist-led clinical review.

Shadeia Younis

Superintendent Pharmacist, Slinic (GPhC 2052119)

Every prescription dispensed by Slinic is clinically verified by Shadeia Younis, our superintendent pharmacist. Treatment recommendations are based on individual clinical assessment and the relevant evidence — not on which medication generates the highest margin.

If Wegovy is the better evidence-based choice for your situation, that is what will be recommended. If a different option suits you better clinically, that’s what you’ll be guided toward.

GPhC Registered Pharmacist GPhC No. 2052119 Superintendent Pharmacist, GPhC Pharmacy 1033729 Specialist in Weight Loss Treatment

Related Guides From Slinic

These guides go deeper on the topics most patients ask about when comparing weight loss injections.

Frequently Asked Questions

Medical Disclaimer

This article provides educational information comparing Wegovy and Saxenda for UK patients and is not a substitute for professional medical advice. Wegovy (semaglutide) and Saxenda (liraglutide) are prescription-only medicines and should only be used together with a reduced-calorie diet and increased physical activity under appropriate clinical supervision. Always consult qualified healthcare providers before starting weight loss medication. Individual results vary. Prices correct as of April 2026 and may be subject to change.